Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
876 stopped studies mapped to Malignant Male Reproductive System Neoplasm and descendants · 91% state a reason
Over the 876 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00452387 | Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone… | Phase 2 | terminated | Mar 27, 2007 | Accelerated Community Oncology Research Network | Early stopping rule | Other (stated, no rule matched) |
| NCT00117312 | Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of… | Phase 2 | terminated | Jul 6, 2005 | Ferring Pharmaceuticals | After 190 weeks \[7 patients left\] it was terminated for administrative reasons | Other (stated, no rule matched) |
| NCT00215657 | Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of… | Phase 2 | terminated | Sep 22, 2005 | Ferring Pharmaceuticals | The doses were not effective in maintaining testosterone suppression | Other (stated, no rule matched) |
| NCT00245466 | Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix… | Phase 2 | terminated | Oct 28, 2005 | Ferring Pharmaceuticals | The maintenance doses were too low to maintain testosterone suppression | Other (stated, no rule matched) |
| NCT00728533 | Open-Label, Randomised Parallel-Group Study | Phase 3 | withdrawn | Aug 6, 2008 | Ferring Pharmaceuticals | Terminated due to awaiting data from Phase II study. | Other (stated, no rule matched) |
| NCT00577356 | Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer | Phase 2 | terminated | Dec 20, 2007 | Benaroya Research Institute | Safety reasons, though no safety issues arose. | Safety / toxicity |
| NCT01116154 | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin… | Phase 1 | terminated | May 4, 2010 | City of Hope Medical Center | Sponsor withdrew support for the study | Other (stated, no rule matched) |
| NCT00952666 | Transrectal Ultrasound Imaging of the Prostate Gland and Neurovascular Bundles During… | Early Phase 1 | terminated | Aug 6, 2009 | Johns Hopkins University | The number of participants needed for this study has been met. | Other (stated, no rule matched) |
| NCT00630799 | Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate… | Phase 3 | terminated | Mar 7, 2008 | GP-Pharm | not stated | Not stated |
| NCT00355758 | UCI 03-72 Prostate Cancer Detection by Serum Proteomic Profiling | — | terminated | Jul 25, 2006 | University of California, Irvine | Lack of personnel | Other (stated, no rule matched) |
| NCT00312442 | Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy | Phase 2 / Phase 3 | terminated | Apr 10, 2006 | STEBA France | STEBA decided to develop WST11 that is soluble in aqueous solutions. The property of WST 11 make it… | Other (stated, no rule matched) |
| NCT00258765 | Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following… | Phase 2 | terminated | Nov 28, 2005 | Novartis Pharmaceuticals | Poor recruitment \& not feasible to continue | Enrollment / accrual |
| NCT00909558 | Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on… | Phase 1 | suspended | May 28, 2009 | Envita Medical Center, Inc. | not stated | Not stated |
| NCT00176527 | Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With… | Phase 2 | terminated | Sep 15, 2005 | University of Medicine and Dentistry of New Jersey | accrual goal met | Enrollment / accrual |
| NCT00391950 | Maintaining Bone Strength in Men With Prostate Cancer | Phase 3 | terminated | Oct 25, 2006 | Novartis | not stated | Not stated |
| NCT00494338 | Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate… | Phase 2 | terminated | Jun 29, 2007 | Sanofi | due to celecoxib safety issues | Safety / toxicity |
| NCT00089856 | GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic… | Phase 3 | terminated | Aug 18, 2004 | Cell Genesys | Based on futility analysis showing \<30% chance of meeting primary endpoint. | Efficacy / futility |
| NCT00133224 | Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in… | Phase 3 | terminated | Aug 23, 2005 | Cell Genesys | Accrual and treatment with CG1940/CG8711 stopped due to IDMC recommendation. | Enrollment / accrual |
| NCT00104130 | Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer | Phase 2 | terminated | Feb 24, 2005 | Bristol-Myers Squibb | not stated | Not stated |
| NCT00273338 | DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC… | Phase 3 | terminated | Jan 9, 2006 | Novacea | DSMB | Other (stated, no rule matched) |
| NCT00255268 | CMAB vs IMAB in Metastatic Prostate Cancer | Phase 4 | withdrawn | Nov 18, 2005 | AstraZeneca | not stated | Not stated |
| NCT00132756 | Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone… | Phase 1 / Phase 2 | terminated | Aug 22, 2005 | Morton Plant Mease Health Care | not stated | Not stated |
| NCT00103623 | The Plenaxis® Experience Study | Phase 4 | suspended | Feb 14, 2005 | PRAECIS Pharmaceuticals Inc. | not stated | Not stated |
| NCT00127088 | Study of Peri-Operative Docetaxel Plus Laparoscopic Radical Prostatectomy in Prostate… | Phase 2 | suspended | Aug 5, 2005 | Gustave Roussy, Cancer Campus, Grand Paris | not stated | Not stated |
| NCT00103428 | Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic… | Phase 1 / Phase 2 | terminated | Feb 9, 2005 | Cell Genesys | not stated | Not stated |
| NCT00179738 | A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of… | Phase 2 | terminated | Sep 16, 2005 | Celgene Corporation | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 16, 2011source: clinicaltrials